Sugi Predict

Sugi Predict / Compounds / SCHEMBL14736337

SCHEMBL14736337

SCHEMBL14736337

CCOc1c(C(C)=O)cc(Cl)c(C)c1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ RAB9A P51151 3/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ LMNA P02545 3/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ GAA P10253 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ ABL1 P00519 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ RIN1 Q13671 1/20 0.40
▸ MITF O75030 1/20 0.39
▸ HTT P42858 2/20 0.38
▸ THRB P10828 1/20 0.38
▸ POLB P06746 2/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ HSD17B10 Q99714 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29836145 1.00 TSHR (0.41) TSHRCYP3A4RAB9AMEN1KMT2A
SCHEMBL14736430 0.86 DRD2 (0.40) TSHRCYP3A4RAB9AMEN1KMT2A
SCHEMBL14753937 0.84 TSHR (0.46) TSHRCYP3A4RAB9AMEN1KMT2A
SCHEMBL18817280 0.82 TSHR (0.44) TSHRCYP3A4RAB9AMEN1KMT2A
SCHEMBL24268233 0.81 CYP3A4 (0.41) TSHRCYP3A4RAB9AMEN1KMT2A
SCHEMBL14736146 0.81 TSHR (0.42) TSHRCYP3A4RAB9AMEN1KMT2A
SCHEMBL23074515 0.81 TSHR (0.42) TSHRCYP3A4RAB9AMEN1KMT2A
SCHEMBL9929315 0.81 CYP3A4 (0.42) TSHRCYP3A4RAB9AMEN1KMT2A
SCHEMBL14735928 0.78 CYP3A4 (0.41) TSHRCYP3A4RAB9AMEN1KMT2A
SCHEMBL14736031 0.78 TSHR (0.41) TSHRCYP3A4RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325550-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE CORP (US) 2025-10-23 — — US disclosed
EP-3888657-B1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE HOLDINGS CORP (US) 2025-03-19 — — EP disclosed
US-12201636-B2 Heterocyclylamines as PI3K inhibitors INCYTE CORPORATION (US) 2025-01-21 — — US disclosed
US-20240216377-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE CORPORATION 2024-07-04 — — US disclosed
US-11819505-B2 Heterocyclylamines as PI3K inhibitors INCYTE CORPORATION (US) 2023-11-21 — — US disclosed
US-20230121440-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE HOLDINGS CORPORATION 2023-04-20 — — US disclosed
US-11433071-B2 Heterocyclylamines as PI3K inhibitors INCYTE CORPORATION (US) 2022-09-06 — — US disclosed
EP-3888657-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS Incyte Holdings Corporation (US) 2021-10-06 — — EP disclosed
EP-3513793-B1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE HOLDINGS CORP (US) 2021-03-10 — — EP disclosed
US-20200323858-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE CORPORATION 2020-10-15 — — US disclosed
US-9730939-B2 Heterocyclylamines as PI3K inhibitors INCYTE HOLDINGS CORPORATION (US) 2017-08-15 — — US disclosed
EP-3196202-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS Incyte Holdings Corporation (US) 2017-07-26 — — EP disclosed
US-9707233-B2 Heterocyclylamines as PI3K inhibitors INCYTE HOLDINGS CORPORATION (US) 2017-07-18 — — US disclosed
EP-2751109-B1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE HOLDINGS CORP (US) 2016-11-30 — — EP disclosed
US-20160022685-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE CORPORATION 2016-01-28 — — US disclosed
US-20160024117-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE CORPORATION 2016-01-28 — — US disclosed
US-9199982-B2 Heterocyclylamines as PI3K inhibitors INCYTE HOLDINGS CORPORATION (US) 2015-12-01 — — US disclosed
EP-2751109-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS Incyte Corporation (US) 2014-07-09 — — EP disclosed
WO-2013033569-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2013-03-07 — — WO disclosed
US-20130059835-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2013-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230121440-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS PIK3CA, PIK3CD, PIK3CB TSHR 3486/4885CYP3A4 1390/4885RAB9A 979/4885
US-20250325550-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS PIK3CA, PIK3CD, PIK3CB TSHR 3486/4885CYP3A4 1390/4885RAB9A 979/4885
US-20240216377-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS PIK3CA, PIK3CD, PIK3CB TSHR 3486/4885CYP3A4 1390/4885RAB9A 979/4885
US-20160024117-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS PIK3CA, PIK3CD, PIK3CB TSHR 3486/4885CYP3A4 1390/4885RAB9A 979/4885
US-11819505-B2 Heterocyclylamines as PI3K inhibitors PIK3CA, PIK3CD, PIK3CB TSHR 3486/4885CYP3A4 1390/4885RAB9A 979/4885
US-11433071-B2 Heterocyclylamines as PI3K inhibitors PIK3CA, PIK3CD, PIK3CB TSHR 3486/4885CYP3A4 1390/4885RAB9A 979/4885
US-20160022685-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS PIK3CA, PIK3CD, PIK3CB TSHR 3486/4885CYP3A4 1390/4885RAB9A 979/4885
US-12201636-B2 Heterocyclylamines as PI3K inhibitors PIK3CA, PIK3CD, PIK3CB TSHR 3486/4885CYP3A4 1390/4885RAB9A 979/4885
US-20200323858-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS PIK3CA, PIK3CD, PIK3CB TSHR 3486/4885CYP3A4 1390/4885RAB9A 979/4885
US-20130059835-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS PIK3CA, PIK3CD, PIK3CB TSHR 3486/4885CYP3A4 1390/4885RAB9A 979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.